Moreover, we evaluate the response of SCLC cells to conventional therapies under KEAP1 silencing, such as chemotherapies with cisplatin and etoposide alone and in combination, as well as to NOTCH inhibition using (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester DAPT molecules. Here, KEAP1 is linked to small cell lung carcinoma.